Dimerix gets first milestone from FUSO Pharma

30 June 2025

Australian biotech Dimerix (ASX: DXB) today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.

Under the FUSO agreement, Dimerix may become eligible to receive further potential success-based development and regulatory milestone payments of up to 3 billion yen (~AU$30.6 million) in further potential development milestones, up to 6.8 billion yen (~AU$69.4 million) in potential sales milestones and tiered royalties from 15% to 20% of DMX 200 net sales in Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK